Category Archives: Cell Medicine

DUBLIN, Sept. 20, 2019 /PRNewswire/ -- The "Global Stem Cell Therapy Market: Focus on Treatment Type, Cell Source, Indication,11 Countries' Data, and Competitive Landscape - Analysis and Forecast, 2019-2029" report has been added to ResearchAndMarkets.com's offering.

Key Questions Answered in this Report:

The Global Stem Cell Therapy Industry Analysis projects the market to grow at a significant CAGR of 27.99% during the forecast period, 2019-2029.

The global stem cell therapy market growth has been primarily attributed to the major drivers in this market such as the increasing prevalence of chronic diseases, rising number of clinical trials for cell-based therapy, steady investment, and consolidation in the regenerative medicine market, and favorable regulatory environment.

The market is expected to grow at a significant growth rate due to the opportunities that lie within its domain, which include product approvals, declining product price, and increasing adoption rate.

However, there are significant challenges which are restraining the market growth. High treatment cost, the exorbitant cost required for set up, and ethical considerations related to the use of embryonic stem cells are the challenges faced by the market.

Key Topics Covered:

Executive Summary

1 Product Definition

2 Scope of the Work2.1 Overview: Report Scope2.2 Segmentation of the Global Stem Cell Therapy Market2.3 Assumptions and Limitations2.4 Key Questions Answered in the Report2.5 Base Year and Forecast Period

3 Research Methodology3.1 Overview: Report Methodology

4 Global Stem Cell Therapy Market4.1 Market Overview4.2 Introduction of Stem Cell Therapy4.3 Application of Stem Cells in Different Therapeutic Areas4.4 Market Dynamics4.5 Global Market Scenario4.6 Assumptions and Limitations

5 Competitive Landscape5.1 Overview5.2 Key Developments and Strategies5.2.1 Collaborations, and Partnerships5.2.2 Approvals and Clinical Studies5.2.3 Funding5.2.4 Business Expansions5.2.5 Product Launches and Developments5.2.6 Mergers and Acquisitions5.2.7 Others5.3 Market Share Analysis

6 Industry Insights6.1 Regulatory Scenario6.2 Regulatory Designations6.3 Expedited Designation Vs. Traditional Approval Timelines:6.4 Regulatory Challenges:

7 Global Stem Cell Therapy Market (by Treatment Type)7.1 Overview7.2 Key Trends of the Global Stem Cell Therapy Market (by Treatment Type)7.3 Autologous Treatment7.4 Allogenic Treatment

8 Global Stem Cell Therapy Market (by Cell Source)8.1 Overview8.2 Key Trends of the Global Stem Cell Therapy Market (by Cell Source)8.3 Bone Marrow and Peripheral Blood8.4 Adipose Tissue8.5 Placenta and Umbilical Cord8.6 Embryo8.7 Others

9 Global Stem Cell Therapy Market (by Indication)9.1 Overview9.2 Key Trends of the Global Stem Cell Therapy Market (by Indication)9.3 Orthopaedic and Dental9.4 Wounds and Injuries9.5 Cardiology and Neurology9.6 Immunology and Inflammatory9.7 Oncology and Metabolism9.8 Others

10 Global Stem Cell Therapy Market (by Region)10.1 Overview10.2 North America10.2.1 Overview10.2.2 U.S.10.2.3 Canada10.3 Europe10.3.1 Overview10.3.2 Germany10.3.3 U.K.10.3.4 France10.3.5 Italy10.3.6 Rest-of-Europe10.4 Asia-Pacific10.4.1 Overview10.4.2 Japan10.4.3 Australia10.4.4 China10.4.5 South Korea10.4.6 India10.4.7 Rest-of-Asia-Pacific10.5 Rest-of-the-World10.5.1 Overview10.5.2 Middle East and Africa10.5.3 Latin America

11 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/nyrlw5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Visit link:
Global Stem Cell Therapy Market Analysis and Forecast, 2019-2029: Focus on Treatment Type, Cell Source, Indication,11 Countries' Data, and Competitive...

Cannibalism among cancer cells is one of the major causes of chemotherapy resistance.

Resistance, which occurs when cancers that have been responding to chemo suddenly begin to grow, is normally associated with the massive production by cancer cells of p-glycoprotein pumps, gene amplification and the repair of DNA breaks caused by some anti-cancer drugs such as doxorubicin, among others.

But cannibalism does exist and while uncommon, adds to the burden of curing or mitigating cancer via chemotherapy.

A new study from Tulane University suggests some cancer cells survive chemotherapy by devouring their neighboring tumor cells in a ruthless bid to withstand chemotherapy. This cellular cannibalism is thought to give predatory cancer cells the energy they need to stay alive. It also allows them to begin tumor relapse after the chemotherapy treatment is completed.

Chemotherapy drugs, among them doxorubicin, kill cancer cells by damaging their DNA. Unfortunately, cancer cells that survive the initial treatment give rise to relapsed tumors.

This is an especially thorny problem in breast cancers that retain a normal copy of a gene called TP53. This protein acts as a tumor suppressor. This means it regulates cell division by keeping cells from growing and proliferating too fast or in an uncontrolled way.

Some cancer cells generally stop proliferating and enter a dormant but metabolically active state known as senescence, instead of dying due to chemotherapy-induced DNA damage. Senescent cancer cells also produce large amounts of inflammatory molecules and other factors that can promote the tumors regrowth.

Chemotherapy-treated breast cancer patients with normal TP53 genes become prone to relapse and have poor survival rates.

Understanding the properties of these senescent cancer cells that allow their survival after chemotherapy treatment is extremely important, Crystal A. Tonnessen-Murray, a postdoctoral research fellow at James G. Jacksons laboratory at the Tulane University School of Medicine, who led the research team, said.

Her team also discovered that senescent breast cancer cells frequently engulf neighboring cancer cells following exposure to doxorubicin or other chemotherapy drugs. Researchers observed this surprising behavior in cancer cells grown in the lab and also in tumors growing in mice.

They also found that lung and bone cancer cells are also capable of engulfing their neighbors after becoming senescent.

Tonnessen-Murray and her colleagues found that senescent cancer cells activate a group of genes, which are normally active in white blood cells, that engulf invading microbes or cellular debris. They saw that after eating their neighboring cancer cells, senescent cancer cells digested them by delivering them to lysosomes, which are acidic cellular structures highly active in senescent cells.

But the most important finding was that this process helps senescent cancer cells stay alive. Senescent cancer cells that engulfed neighboring cells survived in culture for longer than senescent cancer cells that didnt.

The blood test could rapidly confirm whether breast cancer is responding to the drug palbociclib. Miguel . Padrin/Pexels

Continued here:
Cancer Cells Devise Way To Survive Chemotherapy - Medical Daily

Malignant skin cancer is one of the most dangerous types of cancer. 5000 people are diagnosed with it every year in Austria. The number of cases has risen sharply in recent decades. Thirty years ago, there were only five hundred people suffering from malignant melanomas.

In contrast, mortality rates have risen by only a slight margin. If detected early, the chances for recovery are good. But as soon as metastases start to form, the chances for a cure drop rapidly. This is also due to the fact that there are hardly any long-term effective treatment options (source: Austrian Society for Dermatology (GDV).

The Institute for Pharmaceutical Sciences at the University of Graz has been conducting research for many years into natural substances that can be used for the treatment of cancer. The team has now achieved a breakthrough which might also make it possible to cure advanced stages of malignant skin cancer. An active substance from the roots of theOnosma paniculata plant, a subspecies of the borage plant (also known as forget-me-not), has been successfully tested on cancer cells and on mice. The researchers also succeeded in modifying the active ingredient and further improving its effect.

The project was carried out in collaboration with the Technical University of Munich and the Helmholtz Institute Munich (the German Research Center for Environmental Health). The group was led by Rudolf Bauer from the Institute of Pharmaceutical Sciences (Pharmacognosy) at the University of Graz. He has been researching medicinal plants that are used in traditional medicine for fifteen years with the aim of identifying bioactive ingredients and discovering new key substances.

The main purpose of the research was to identify the plants that are used in traditional Chinese medicine (TCM) as cures for cancer-related diseases. Cancer-related, because the definition of cancer in TCM differs from that in Western medicine, Nadine Kretschmer explains. She has worked with the project and is a biologist at the Heidelberg University of Medicine. Another goal was to test their suitability as an active substance for a particular medicine. Approximately eighty percent of all Chemotherapeutic drugs are derived from nature, especially from plants. This figure is as high as seventy percent just for cancer therapies. The active substances on the market are usually synthetically modified even more so that they have an optimal effect. The active substances are then usually produced synthetically or biotechnologically for commercial purposes, Kretschmer says.

The contribution made by the University of Graz to the project was based on a database of several hundred medicinal plants used in traditional medicine which have been accumulated over several years. This project focused on plants from traditional Chinese medicine (TCM). Part of the contribution made by the German partners was the implementation of RNA (ribonucleic acid) sequencing and preliminary evaluations. RNA sequencing serves as a means of determining the nucleotide sequence in the RNA and provides information on how the genetic information of a gene is expressed.

The project included seventy-six of the most promising specimens from the database. These were dried, processed into 253 extracts and tested on various cancer cells. In the end, it was the Onosma Paniculata Bureau & Franch, a type of borage shrub, that offered prospects for further studies. The potent substance --Dimethylacrylshikonin (DMAS) is found in the root of the plant.

During the experiments, the substance was tested on cells of malignant melanomas. The substance destroyed the cells thereby confirming their efficacy. In order to test the substance for side effects, the initial in vivo tests were carried out on mice that were afflicted with skin cancer. - dimethylacrylshikonin was injected directly into the tumor which caused it to change and die off. Two types of cell death were observed:

There were no side effects.

Subsequent trials were conducted expressly with the aim of modifying the substance in order to improve its efficacy. A specific shikonin derivative proved to be especially effective. This demonstrated that the substance is well suited for the development of pharmaceuticals. In the meantime, two more follow-up projects have been planned. More extensive studies are required and the method of application is still an open question, Kretschmer states.

Kretschmer emphasizes that TCM was purely an inspiration for the active substance. It is still not clear how this works within TCM. Normally no singular plants are used in TCM, instead plant mixtures are used. These are prepared like tea. In an attempt to unravel the effect of TCM, the team cooked up the dried plant according to the TCM method and used it in cell cultivation experiments. However, no anti-tumor effect was observed. Kretschmer sees more potential in an oil-based preparation method that is applied to the affected areas of the skin. This is because shikonins are found in higher concentrations in the oil.

Over the course of the project, the identity of the borage plant species sold as TCM remedies was also tested. There are roots that look very similar to the plant we are studying and we have found that the species is often sold under fake names in China. This is problematic because some of the plants that are marketed contain substances that are potentially harmful.

Kretschmer and the research team found a technical solution to the problem: a method which uses thin-layer chromatography for the identification of plants. This innovation is based on a CAMAG system and is simple enough for use in pharmacies.

Thin-layer chromatography (TLC) is a physicochemical separation process that is used to examine the composition of specimens.

The core project was funded by the Austrian Science Fund FWF and was completed in early 2019.

Publications:

Kretschmer, N.; Deutsch, A.; Durchschein, C.; Rinner, B.; Stallinger, A.; Higareda-Almaraz, J.C.; Scheideler, M.; Lohberger, B.; Bauer, R.: Comparative Gene Expression Analysis in WM164 Melanoma Cells Revealed That --Dimethylacrylshikonin Leads to ROS Generation, Loss of Mitochondrial Membrane Potential, and Autophagy Induction, in: Molecules 2018, 23

Durchschein, C.; Hufner, A.; Rinner, B.; Stallinger, A.; Deutsch, A.; Lohberger, B.; Bauer, R.; Kretschmer, N.: Synthesis of Novel Shikonin Derivatives and Pharmacological Effects of Cyclopropylacetylshikonin on Melanoma Cells, in: Molecules 2018, 23

Jahanafrooz, Z; Stallinger, A; Anders, I; Kleinegger, F; Lohberger, B; Durchschein, C; Bauer, R; Deutsch, A; Rinner, B; Kretschmer, N.: Influence of silibinin and --dimethylacrylshikonin on chordoma cells, in: Phytomedicine 2018, 49

Also of interest:

Dual Therapy to Reduce the Relapse Rate in Cancers

Innovation Origins is an independent news platform, which has an unconventional revenue model. We are sponsored by companies that support our mission: spreading the story of innovation. Read more here.

On Innovation Origins you can always read articles for free. We want to keep it that way. Have you enjoyed this article so much that you want to contribute to independent journalism? Click here:

Link:
Plant used in traditional Chinese medicine is effective against malignant skin cancer - Innovation Origins

Batavia Biosciences has announced that the company has signed a license agreement to utilize Horizon Discoverys GS knockout CHO K1 cell line expression system for the development of high yield antibody-expressing cell lines. Initially, Batavia will deploy the system for production of a potent Zika virus neutralizing antibody, working in collaboration with Vanderbilt University Medical Center (VUMC) and IDBiologics, a company which focuses on developing human antibodies for the prevention, treatment and cure of infectious diseases.

The Zika virus neutralizing antibody was discovered three years ago by VUMC researchers in collaboration with colleagues at Washington University School of Medicine in St. Louis. The group reported isolation of a human monoclonal antibody that in a mouse model markedly reduced infection by the Zika virus. The VUMC antibody, dubbed ZIKV-117, binds to an epitope or part of the Zika virus in a way that no other antibody has to date.

Were excited to work with Batavia to move this promising Zika antibody therapy one step closer to the clinic, stated James Crowe Jr, M.D., Director of the Vanderbilt Vaccine Center.

Developing high yield antibody producer CHO lines is difficult and expensive, added Robert Carnahan, Ph.D., Director of Vanderbilt Antibody and Protein Resource. That is why this new solution is so important to the anti-Zika antibody project.

The mosquito-borne Zika virus is believed to cause microcephaly (unusually small heads) and other congenital malformations in children born to infected women. Currently, there is no way to prevent Zika virus infection or its aftermath.

Menzo Havenga, CEO, Batavia Biosciences, explained: We are thrilled to now have access to Horizons expression system to complement our existing STEP technology for recombinant protein production and to have VUMC and IDBiologics as collaborators on the development of a much needed Zika virus medical countermeasure.

Chuck Haines, CEO, IDBiologics commented: We are looking forward with great anticipation to receiving the Zika virus antibody cell line from the VUMC-Batavia collaboration and continuing to advance this product to the clinic.

Horizon licenses its CHO expression system to pharmaceutical, biotechnology, and biosimilar companies, as well as contract manufacturing organizations. The system includes the GS knockout CHO K1 cell line, a comprehensive package of supporting documentation, and an expression vector supplied under license from DNATwoPointO, Inc. Dirk Gewert, Business Unit Director, Horizon Discovery explained: This proprietary solution has now been featured in a number of confirmed Investigational New Drug (IND) filings. This solution allows companies to move from the DNA sequence of their potential biotherapeutic to clinical manufacturing as simply and rapidly as possible. Both Horizon and Batavia are dedicated to ensure availability of key technologies that can improve affordability of medicines worldwide.

For more science news, straight to your inbox, join SelectScience today >>

Original post:
Industry News: Batavia Biosciences to deploy Horizon Discovery's CHO cell technology to develop anti-Zika biotherapeutic with Vanderbilt University...

Committed to the advancement and pursuit of knowledge, through the achievement of breakthroughs in biomedical research and through the provision of outstanding educational content

The Department of Cell, Developmental and Integrative Biology (CDIB) is a nationally ranked basic science department within the prestigious UAB School of Medicine. In recognition of their research and teaching successes, our outstanding CDIB faculty have earned numerous awards, both locally and nationally. From a financial standpoint, our faculty currently manage in excess of $16M in annual direct costs from extramural funding to support their research programs. Furthermore, our distinguished educators deliver educational content within six schools across UAB and, as a result, have a major impact in countless lives.

CDIB faculty direct five robust and diverse research programs and garner substantial international and national recognition for themselves, as well as our department, and our institution. Faculty research, scientific service, leadership, and scholarly activities reflect our departments vision of uniting exemplary, multidisciplinary academic scholarship, education and research.

CDIB faculty make lasting, noteworthy contributions to the Universitys educational mission both within and beyond the institution. Our educational endeavors range from K-12 and adult educational outreach, to lectures and preceptorships in multiple courses across campus, to leadership roles within the professional and graduate schools.

Continue reading here:
UAB - School of Medicine - Cell, Developmental and ...

With over 25 years of experience, Dr. Wagner is highly regarded as a leader in the field of Sports Medicine. As an expert in the field, he has treated some of the biggest names in sports. From professional, collegiate and high school athletes to recreational "weekend warriors," it remains Dr. Wagners goal to provide his patients with individualized, state of the art treatment, returning them to their games as quickly as possible.

Dr. Wagner is proud to be voted Seattle Met's "Top Doctor" for 2017 by his colleagues in the greater Seattle area.

Dr. Wagner has a special interest in Regenerative Medicine and joint preservation through the use of autologous stem cells. This exciting, nonsurgical procedure has shown great promise in restoring, repairing and regenerating arthritic joints and damaged tendons, providing an alternative to many who believed that surgery was the only option. Dr. Wagner has treated hundreds of patients with these procedures in his office with overwhelming success.

Dr. Wagner received his medical degree from the University of South Florida in Tampa, Florida. He completed his residency in Family Practice and Sports Medicine at Halifax Hospital Medical Center in Daytona Beach, FL. Dr. Wagner came to Seattle to complete a fellowship in sports medicine at The Sports Medicine Clinic.

He is board certified by the American Board of Family Practice with a subspecialty in Sports Medicine. He is also a member of the American College of Sports Medicine, the Washington Academy of Family Physicians, the Washington State Medical Society and the King County Medical Society.

Dr. Wagner lives on beautiful Bainbridge Island with his wife and three children. When out of the office, he enjoys spending time in the outdoors hiking, surfing, bicycling and snow skiing with his family. Always up for a personal challenge, he has enjoyed competing in such races as the Coeur D'Alene Ironman, Seattle and Vancouver Marathons and RAMROD.

Read the original here:
Seattle Stem Cell & Regenerative Medicine

Responsibility

The organizers holds no responsibilities orliabilities of the personal articles of attendees at the venue against any kindof theft, lost, damage, due to any reason whatsoever. Delegates are entirelyresponsible for the safety of their own belongings.

Insurance

No insurance, of any kind, is included along withthe registration in any of the events of the organization.

Transportation

Please note that transportation and parking is the responsibilityof the registrant, Allied Academies will not be liable for any actionshowsoever related to transportation and parking.

Press/Media

Press permission must be obtained from AlliedAcademies Conference Organizing Committee prior to the event. The press willnot quote speakers or delegates unless they have obtained their approval inwriting. The Allied Academies is an objective third-party nonprofitorganization and this conference is not associated with any commercial meetingcompany.

Requesting an Invitation Letter

For security purposes, letter of invitation will besent only to those individuals who had registered for the conference afterpayment of complete registration fee. Once registration is complete, pleasecontactstemcell@alliedevents.org

Cancellation Policy

All cancellations or modifications of registrationmust be made in writing to finance@alliedacademies.com

If, due to any reason, Allied academies postpone anevent on the scheduled date, the participant is eligible for a credit of 100%of the registration fee paid. This credit shall only be used for another eventorganized by Allied academies within period of one year from the date ofrescheduling.

Postponement of event

If, due to any reason, Allied academies postpone anevent and the participant is unable or unwilling to attend the conference onrescheduled dates, he/she is eligible for a credit of 100% of the registrationfee paid. This credit shall only be used for another event organized by Alliedacademies within period of one year from the date of rescheduling.

Transfer of registration

All registrations, after payment of completeregistration fee, are transferable to other persons from the same organization,if in case the person is unable to attend the event. Request for transfer ofregistration must be made by the registered person in writing to contacts@alliedacademies.com Details mustinclude the full name of replaced new registrant, their title, contact phonenumber and email address. All other registration details will be assigned tothe new person unless otherwise specified. Registration can be transferred toone conference to another conference of Allied academies if the person isunable to attend one of conferences.

However, Registrationcannot be transferred if intimated within 14 days of respective conference.

The transferredregistrations will not be eligible for Refund.

This cancellation policywas last updated on April 04, 2015.

Visa Information

Keeping in view of increased security measures, wewould like to request all the participants to apply for Visa as soon aspossible.

Allied academies will notdirectly contact embassies and consulates on behalf of visa applicants. Alldelegates or invitees should apply for Business Visa only.

Important note for failed visa applications: Visaissues are not covered under the cancellation policy of Allied academies,including the inability to obtain a visa.

Refund Policy.

If the registrant is unable to attend, and is notin a position to transfer his/her participation to another person or event,then the following refund policies apply:

Keeping in view of advance payments towards Venue,Printing, Shipping, Hotels and other overhead charges, following Refund Policy

Orders are available:

Accommodation Cancellation Policy

Accommodation Service Providers (Hotels) have theirown cancellation policies which are applicable when cancellations are made lessthan 30 days prior to arrival. If in case the registrant wishes to cancel oramend the accommodation, he/ she is expected to inform the organizingauthorities on a prior basis. Allied academies will advise the registrant toensure complete awareness about the cancellation policy of your accommodationprovider, prior to cancellation or modification of their booking.

Original post:
Stem Cell | Regenerative medicine | 2019 | Conference ...

Bone Marrow & Stem Cell Transplant

The Bone Marrow and Stem Cell Transplant Program at Weill Cornell Medicine was established with the mission of providing the best care and most innovative research in a compassionate and comfortable environment.

We take a multidisciplinary approach to care for patients with cancer and blood diseases who need stem cell transplants, providing world-class clinical care in collaboration with experts in leukemia, lymphoma, myeloma and other blood disorders. Based at NewYork-Presbyterian/Weill Cornell Medical Center, one of the top ten general hospitals in the nation, the expertise of our consulting team is unsurpassed.

Our patients and families cope with life-threatening illness; as such, sensitivity and compassion are a priority for our team. We view each patient as an individual, and our approach ensures that each treatment regimen is narrowly tailored to meet the unique, changing needs of our patients and their families before, during and after transplant.

As New Yorks premier healthcare institution, Weill Cornell Medicine is at the forefront of scientific research and clinical trials, enabling us to provide a full range of diagnostic and treatment protocols, including the latest breakthroughs in medicine.

Our Team

Our team of internationally-recognized bone marrow transplant and stem cell surgery specialists is known for advanced work and published research in:

Treating patients with aggressive leukemia and myelodysplastic syndromes

Bridge protocols for patients with refractory lymphoma and leukemia

Novel strategies to mobilize stem cells and improve transplantation for patients with multiple myeloma, leukemia and lymphoma

Transplants for solid tumors, severe auto-immune disorders, and AIDS

Treatment

We pride ourselves on exceptional outcomes and offer patients the most advanced diagnostic methods and treatment therapies to improve quality of life, including:

Umbilical cord blood transplant

Outpatient transplant

Autologous stem cell transplant; uses stem cells extracted from the bone marrow or peripheral blood of the patients own blood

Allogeneic stem cell transplant; uses stem cells extracted from the bone marrow or peripheral blood of a matching donor

Hematopoietic stem cell transplant; used to treat certain cancers of the blood/bone marrow, including leukemia and myeloma

Matched unrelated donor stem cell transplantation through the National Donor Matching Program

Non-ablative "mini" transplants

Haplo-Cord Transplant, allowing us to find donors for all patients, regardless of age or ethnic background

Bendamustine, a therapy that is well-tolerated and has excellent response rates in patients with myeloma

Novel forms of transplant, offering hope and success to older patients with leukemia

Clinical Trials

Clinical trials are important to improve outcomes and offer new treatment options. At Weill Cornell Medicine, we conduct more studies in blood cancers than any of our regional peers, allowing us to provide our patients with access to many multi-phase clinical trials. As active members of the international cancer research community, our oncologists also collaborate with other research centers to offer patients the most promising treatments available.

Second Opinions

In concert with your referring physician, we are always available to offer a second opinion in the form of a consultation with one of our specialists.

Why Choose Us?

Our collaborative approach means our patients receive supportive, comprehensive care and the most cutting-edge stem cell therapy and treatments. This enables patients to receive the best possible transplant outcomes. Additionally, we offer more allogeneic stem cell transplants for older adults than any other center in New York City and the entire tri-state area.

For more information or to schedule an appointment, call us at 212-746-2119 or 212-746-2646.

Located in New York City, Weill Cornell Medical College is ranked among the nations best by U.S. News & World Report year after year.

Read more from the original source:
Bone Marrow & Stem Cell Transplant | Weill Cornell Medicine

Department of Cell Biology & Molecular Medicine - Home

Through its medical and graduate programs, the department offers training and research opportunities that prepare medical, dental, and graduate students, as well as postdoctoral fellows, for careers in medicine and biomedical research. Departmental research focuses on the physiological, developmental, cellular, molecular, and environmental factors responsible for the initiation and progression of human disease. Faculty research interests include regulation of gene expression, DNA repair, mitochondrial stability, cell cycle control, and signal transduction pathways in normal and diseased tissue, with particular emphasis on cardiovascular control, cardiovascular disease, cancer, angiogenesis, and the application of stem cells for regenerative medicine. Approaches include animal models of cardiac disease, cutting-edge technologies in cell biology, molecular biology, molecular genetics, genomics, and proteomics, and advanced histological and cell / tissue culture methods. The department has access to exceptional laboratory and animal facilities, equipment, and computational services, as well as to shared, state-of-the-art, core research facilities providing transgenic, molecular, genomic, proteomic, microscopic, flow cytometry, and biostatistics/bioinformatics support. Potential applicants are encouraged to use this web site to learn more about our research and training opportunities.

See the rest here:
Rutgers New Jersey Medical School

Stem Cell Therapy is a revolutionary medical breakthrough with the potential to treat health problems that have been resistant to other forms of treatment. Stem cell therapy is a form of regenerative medicine that treats the body at the cellular-level. This therapy targets diseased or damaged tissue and organs by introducing cells to replace damaged cells. Stem cells are so effective because of their ability to differentiate into cells that carry out the roles needed in a variety of organs.

Regenerative medicine like stem cell therapy is used to treat a variety of medical conditions across specialties such as rheumatology, orthopedics, neurology, immunology, and cardiology. While stem cell therapy is used to treat pre-existing conditions, it can also be used preventatively. Because of the minimally invasive and potentially beneficial applications of stem cell therapy, many patients take regular stem cell treatments to help prevent against potential future complications.

Stem cells make the most efficient use of the bodys natural ability to heal itself by targeting health issues at the cellular level. This is why regenerative medicine such as stem cell therapy harnesses the ultimate potential for the future of medical treatment.

See original here:
Cell MD - Stem Cells for Regenerative Medicine